Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.
- DOI
- 10.1007/s12325-025-03479-y
- Published
- 2026 Mar
- Container
- Advances in therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-025-03479-y,
title = {Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.},
author = {Lopez-Muñoz N and Bar N and Diels J and van Sanden S and Mendes J and Lee S and Hernando T and Lendvai N and Patel N and Ishida T and Er J and Harrison SJ},
year = {2026},
journal = {Advances in therapy},
doi = {10.1007/s12325-025-03479-y},
url = {https://doi.org/10.1007/s12325-025-03479-y}
}RIS
TY - JOUR TI - Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. AU - Lopez-Muñoz N AU - Bar N AU - Diels J AU - van Sanden S AU - Mendes J AU - Lee S AU - Hernando T AU - Lendvai N AU - Patel N AU - Ishida T AU - Er J AU - Harrison SJ PY - 2026 JO - Advances in therapy DO - 10.1007/s12325-025-03479-y UR - https://doi.org/10.1007/s12325-025-03479-y ER -
APA
N, L., N, B., J, D., S, V. S., J, M., S, L., T, H., N, L., N, P., T, I., J, E., & SJ, H. (2026). Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.. Advances in therapy. https://doi.org/10.1007/s12325-025-03479-y
Source records
- pubmed · retrieved 2026-09-26T14:25:58.011Z